Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes
Type 2 diabetes (T2D) is a chronic disease associated with a high epidemiological and economic burden. It is associated with a high risk of developing both macrovascular and microvascular complications and cardiovascular diseases represent the main cause of mortality and morbidity in T2D patients. T...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2020-12-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1490 |
| _version_ | 1818930860023349248 |
|---|---|
| author | Edoardo Mannucci Pier Paolo Mangia Lorenzo Pradelli |
| author_facet | Edoardo Mannucci Pier Paolo Mangia Lorenzo Pradelli |
| author_sort | Edoardo Mannucci |
| collection | DOAJ |
| description | Type 2 diabetes (T2D) is a chronic disease associated with a high epidemiological and economic burden. It is associated with a high risk of developing both macrovascular and microvascular complications and cardiovascular diseases represent the main cause of mortality and morbidity in T2D patients. The economic impact of diabetes is primarily due to the cost and duration of treatment and secondary complications of diabetes and associated costs. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are an effective therapy for providing a long-term improvement of glucose control, thus contributing to the long-term prevention of diabetic (particularly microvascular) complications. Furthermore, SGLT-2 inhibitors seem to lead to significant reductions in hospital admissions due to heart failure and progression of renal disease, regardless of baseline atherosclerotic risk category or history of heart failure. Evidence from randomized controlled trials, observational and pharmacoeconomic studies suggest that SGLT2 inhibitors should be considered not only in patients with established cardiovascular disease and incipient nephropathy but also in earlier stages of T2D in order to prevent the first onset of cardiovascular and renal complications and contain the cost of illness. |
| first_indexed | 2024-12-20T04:07:24Z |
| format | Article |
| id | doaj.art-edceb47d837249ec80bc70d83fe7944c |
| institution | Directory Open Access Journal |
| issn | 2240-256X |
| language | English |
| last_indexed | 2024-12-20T04:07:24Z |
| publishDate | 2020-12-01 |
| publisher | SEEd Medical Publishers |
| record_format | Article |
| series | Farmeconomia: Health Economics and Therapeutic Pathways |
| spelling | doaj.art-edceb47d837249ec80bc70d83fe7944c2022-12-21T19:54:00ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2020-12-01211S10.7175/fe.v21i1S.14901327Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 DiabetesEdoardo Mannucci0Pier Paolo Mangia1Lorenzo Pradelli2Diabetology, Careggi Hospital and University of Florence, Florence, ItalyAdRes HE&OR, Turin, ItalyAdRes HE&OR, Turin, ItalyType 2 diabetes (T2D) is a chronic disease associated with a high epidemiological and economic burden. It is associated with a high risk of developing both macrovascular and microvascular complications and cardiovascular diseases represent the main cause of mortality and morbidity in T2D patients. The economic impact of diabetes is primarily due to the cost and duration of treatment and secondary complications of diabetes and associated costs. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are an effective therapy for providing a long-term improvement of glucose control, thus contributing to the long-term prevention of diabetic (particularly microvascular) complications. Furthermore, SGLT-2 inhibitors seem to lead to significant reductions in hospital admissions due to heart failure and progression of renal disease, regardless of baseline atherosclerotic risk category or history of heart failure. Evidence from randomized controlled trials, observational and pharmacoeconomic studies suggest that SGLT2 inhibitors should be considered not only in patients with established cardiovascular disease and incipient nephropathy but also in earlier stages of T2D in order to prevent the first onset of cardiovascular and renal complications and contain the cost of illness.https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1490sglt2i, pharmacoutilizationcardiovascular protectioncomplications, type 2 diabetes |
| spellingShingle | Edoardo Mannucci Pier Paolo Mangia Lorenzo Pradelli Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Farmeconomia: Health Economics and Therapeutic Pathways sglt2i, pharmacoutilization cardiovascular protection complications, type 2 diabetes |
| title | Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes |
| title_full | Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes |
| title_fullStr | Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes |
| title_full_unstemmed | Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes |
| title_short | Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes |
| title_sort | clinical and economic rationale for the early use of sglt2 inhibitors in patients with type 2 diabetes |
| topic | sglt2i, pharmacoutilization cardiovascular protection complications, type 2 diabetes |
| url | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1490 |
| work_keys_str_mv | AT edoardomannucci clinicalandeconomicrationalefortheearlyuseofsglt2inhibitorsinpatientswithtype2diabetes AT pierpaolomangia clinicalandeconomicrationalefortheearlyuseofsglt2inhibitorsinpatientswithtype2diabetes AT lorenzopradelli clinicalandeconomicrationalefortheearlyuseofsglt2inhibitorsinpatientswithtype2diabetes |